Overview
Cotempla XR-ODT (methylphenidate extended-release orally disintegrating tablet) is a central nervous system (CNS) stimulant indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in pediatric patients 6 to 17 years of age.

Coverage Guidelines
Authorization may be granted when ALL the following criteria are met:
1. Member has a diagnosis of attention deficit hyperactivity disorder (ADHD) or autism spectrum disorder (ASD) AND
2. Prescriber has provided documentation of an inadequate response, adverse reaction, or contraindication to Concerta® (methylphenidate extended-release) AND
3. Prescriber has provided documentation of an inadequate response, adverse reaction, or contraindication to Focalin XR® (dexamfetamine extended-release).

Please note: Additional criteria may apply for members under the age of 18. Please refer to the MassHealth Pediatric Behavioral Health Medication Initiative guideline for criteria.

Continuation of Therapy
Reauthorization requires physician documentation indicating a positive response to therapy.

Limitations
1. Approvals will be granted for 12 months.
2. The following quantity limits apply:
Appendix
Adverse reactions/contraindications to stimulants include but are not limited to weight loss or failure to gain weight, insomnia, agitation, increased anger and aggression, tic disorder, seizures w/ ADHD, traumatic brain injury w/ ADHD (trial of both a methylphenidate product and amphetamine product is required for approval), symptomatic heart disease in children (tachycardia or hypertension), symptomatic heart disease in adults (there should be at least 1 failed trial of another non-stimulant medication that may be used for ADHD such as bupropion.)

References
N/A

Review History
03/01/18 – Implemented MassHealth PDS

Disclaimer
AllWays Health Partners complies with applicable federal civil rights laws and does not discriminate or exclude people on the basis of race, color, national origin, age, disability, or sex.